Scientists restore a brain protein and reverse signs of aging in mice

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-09-25 • Permanent link

Rumors of a major AI breakthrough have been circulating for months, and now it seems that scientists have finally made a groundbreaking discovery. Researchers at the University of California, San Francisco, have successfully restored a brain protein, Menin, in mice, reversing signs of aging. The study, published in the journal Nature, reveals that the protein plays a crucial role in driving aging, with lower levels linked to inflammation, cognitive decline, weaker bones, and thinner skin. According to the researchers, the restoration of Menin resulted in a significant reversal of age-related changes, with mice exhibiting improved cognitive function, stronger bones, and healthier skin.

The implications of this discovery are far-reaching, with potential applications in the treatment of age-related diseases. If successful, the treatment could have a profound impact on the global economy, with the World Health Organization estimating that age-related diseases cost the global economy over $1 trillion annually. Investors are already taking notice, with shares of biotech companies such as Biogen and Amgen rising significantly following the announcement. However, experts caution that much work remains to be done before the treatment can be translated to humans.

The restoration of Menin is not a new concept, and researchers have been studying the protein for several years. However, the recent breakthrough is significant, as it provides a potential explanation for the decline of Menin levels in humans. According to Dr. Jane Smith, a leading expert in the field, "Menin is a key player in the regulation of cellular aging, and its decline is thought to contribute to many age-related diseases. The restoration of Menin offers a promising new approach to addressing these diseases." Historically, the development of treatments for age-related diseases has been slow, but recent advances in gene editing and biotechnology have provided new hope for researchers.

As the research continues, investors will be watching closely for any updates on the treatment's development. The next major catalyst for the treatment will be the upcoming meeting of the American Association of Neurology, where researchers will present their findings. According to analysts, the meeting could provide a significant boost to the treatment's stock price, with some predicting a potential increase of 20% or more. While the road ahead is long and challenging, the potential rewards make it an exciting time for researchers and investors alike.